Detalles de la búsqueda
1.
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
Br J Cancer
; 115(9): 1069-1077, 2016 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27673365
2.
Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.
Cancer Res Commun
; 4(6): 1441-1453, 2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727208
3.
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Blood
; 116(12): 2089-95, 2010 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-20548094
4.
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Mol Cancer Ther
; 20(10): 1757-1768, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34330842
5.
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Br J Haematol
; 150(1): 46-57, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20507304
6.
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Mol Cancer Ther
; 8(2): 324-32, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19174555
7.
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Mol Cancer Ther
; 17(7): 1381-1391, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29695633
8.
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
J Med Chem
; 61(11): 4978-4992, 2018 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29775310
9.
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Leuk Lymphoma
; 58(6): 1358-1365, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27750483
10.
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
Cancer Res
; 63(1): 196-206, 2003 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12517798
11.
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Eur J Cancer
; 61: 94-101, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27156227
12.
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
Cancer Res
; 76(9): 2731-42, 2016 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27197266
13.
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
Clin Cancer Res
; 21(2): 267-73, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25370467
14.
Raf pathway inhibitors in oncology.
Curr Opin Investig Drugs
; 4(12): 1436-41, 2003 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-14763129
15.
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
Mol Cancer Ther
; 13(12): 2793-2804, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25349308
16.
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Clin Cancer Res
; 18(14): 3912-23, 2012 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22781553
17.
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
Leuk Lymphoma
; 57(6): 1463-6, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26376958
18.
Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation.
PLoS One
; 6(9): e25683, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21984938
19.
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Mol Cancer Ther
; 9(4): 920-8, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20354122
20.
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Mol Cancer Ther
; 9(5): 1100-10, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20423992
Resultados
1 -
20
de 20
1
Próxima >
>>